Cell Therapeutics Inc (NASDAQ:CTIC)’s shares jumped 3.09% to $3.51. Cell Therapeutics to benefit from Geron troubles, says Roth Capital. After Geron’s (GERN) telomerase inhibitor for myelofibrosis and other settings was put on full clinical hold due to potential liver injury, Roth Capital thinks that the competitive positioning of CTIC’s myelofibrosis treatment, Pacritinib, has improved. The firm keeps a Buy rating on Cell Therapeutics. Cell Therapeutics Inc (NASDAQ:CTIC) shares after opening at $3.42 moved to $3.60 on last trade day and at the end of the day closed at $3.58. Company price to sales ratio in past twelve months was calculated as 15.44 and price to cash ratio as 7.48.
Gastar Exploration INC. (NYSEMKT:GST) rose on Tuesday after the company announced it would hold an analyst meeting on April 2 to discuss, among other things, its expanded Marcellus Shale drilling inventory. GASTAR EXPLORATION, INC. (NYSEMKT:GST) shares advanced 11.33% in last trading session and ended the day on $6.09. GST return on equity ratio is recorded as 68.60% and its return on assets is 12.50%. GASTAR EXPLORATION, INC. (NYSEMKT:GST) yearly performance is 195.63%.
Research analysts at JMP Securities cut their target price on shares of Horizon Pharma (NASDAQ:HZNP) from $22.00 to $21.00 in a report released on Friday, ARN reports. The firm currently has an “outperform” rating on the stock. Horizon Pharma Inc (NASDAQ:HZNP) shares moved up 6.28% in last trading session and was closed at $16.07 while trading in range of $15.21 – $16.25 – Horizon Pharma Inc (NASDAQ:HZNP) year to date (YTD) performance is 110.89%.
Shares of JA Solar Holdings Co. (NASDAQ:JASO) were the target of unusually large options trading on Tuesday. Stock investors acquired 12,468 call options on the company,American Banking and Market News reports. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) weekly performance is 6.67%. On last trading day company shares ended up $11.04. JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) distance from 50-day simple moving average (SMA50) is 8.85%. Analysts mean target price for the company is $12.40.